Canaccord Genuity Maintains a 'Buy' on Teva Pharma (TEVA); 2012: Focus on Guidance, Cash Deployment. & Valuation
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $37.34 +1.44%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.
Canaccord analyst, Randall Stanicky, said, "TEVA last week announced that it will host its 2012 update call before year-end as anticipated, with the call to take place this Wednesday morning. Since then we’ve received a steady stream of calls with most looking to gauge (1) what to expect and (2) where broader investor expectations are. On that note, we’ve taken a deeper look at these two questions in this report with a focus on 2012 guidance, capital deployment and valuation – three things that we’ve been focused on since late September. Our bottom line on the stock is unchanged: it remains our top idea near term with expectations reasonable, sentiment low and valuation leaving room for a further move to the upside."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $42.72 yesterday.
Canaccord analyst, Randall Stanicky, said, "TEVA last week announced that it will host its 2012 update call before year-end as anticipated, with the call to take place this Wednesday morning. Since then we’ve received a steady stream of calls with most looking to gauge (1) what to expect and (2) where broader investor expectations are. On that note, we’ve taken a deeper look at these two questions in this report with a focus on 2012 guidance, capital deployment and valuation – three things that we’ve been focused on since late September. Our bottom line on the stock is unchanged: it remains our top idea near term with expectations reasonable, sentiment low and valuation leaving room for a further move to the upside."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $42.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Benchmark Reiterates Buy Rating on Rank One Computing (ROC)
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
